Brookside Capital

They design, implement, and manage custom tailored portfolios of liquid assets for high net worth investors.

Business Model:

Revenue: $30.5M

Employees: 51-200

Rankings

Detailed Brookside Capital Information

Geographic Data

Brookside Capital headquarters map

Address: 2269 Chestnut St

City: San Francisco

State: CA

Zip: 94123

Country: US

Financial Info

Stage:

Raised Last:

$0

Raised Total:

$0

Metrics

0Website Global Rank

0Website Monthly Traffic

Twitter Followers

Description

They design, implement, and manage custom tailored portfolios of liquid assets for high net worth investors. In order to avoid the potential conflict of interest found in most of the financial industry, they do not accept commissions on any transactions in client accounts. They sell no assets. Instead, they charge a management fee that is based on the market value of the account. That fee ranges from 1.5% per year down to 0.5%, depending on the size of the account. For the safety of the client’s assets, they do not hold cash or securities at Brookside Capital, Inc. Assets are held at a brokerage firm or bank custodian of the client’s choice. The minimum account size is generally $1 million. There is a wide range of issues to consider when designing a portfolio strategy for a client. Among these issues are age, other assets held, income requirements, taxes, specific funding goals, and personal preferences. However, the most important consideration is defining the acceptable level of risk for each client. They have found that this is both a financial and comfort level that varies broadly by client. Through financial modeling and some proprietary questionnaires, they help the client understand their specific acceptable risk level, and then design a strategy that optimizes the potential rate of return without exceeding that risk limit. Stated simply, all clients want to make as much money as they can—without exceeding their own unique risk level. In selecting assets, they start the decision process at what they call the “SEP” level. SEP stands for “Social, Economic, and Political” themes. Their research has unquestionably shown that understanding these global, long-term themes is the most essential element in determining investment success or failure. Their Board of Advisors is the key group in helping them understanding these themes. Some examples include The Revolution in Healthcare, Homeland Security, Consumer Value, The Information Age: Part 3, Nanometrics, and The Education Failure. There are many others, and the list is fluid and always evolving. They meet with their clients often to keep them up to date on their portfolios and their outlook. This also gives them the opportunity to keep their current on any changes in their lives so that they can make any necessary adjustments in their portfolio strategy.

Contact Phone:
+14152334640

Contact Email:

Announced Date Company Transaction Money Raised
11/2007 Youku Series C 25M
2/2007 Targanta Therapeutics Series C 70M
5/2014 Spark Therapeutics Series B 72.8M
5/2005 MetaSolv Venture Round 21.9M
3/2008 Thumbplay Series E 18M
4/2015 Voyager Therapeutics Series B 0
5/2008 Sohu.com Post-IPO Equity 25M
4/2013 Radius Health Private Equity Round 43M
7/2005 Eyetel Imaging Series B 17.7M
12/2009 Youku Series E 40M
6/2008 Youku Series D 40M
1/2007 diaDexus Post-IPO Equity 0
11/2015 Socar Series B 56.4M
1/2006 Perlegen Sciences Series D 0
2/2005 Perlegen Sciences Series D 0
3/2007 MAP Pharmaceuticals Series D 50M
4/2010 Brightcove Series D 12M
7/2015 Qoo10-Indonesia Series A 0
7/2015 Translate Bio Series B 0
1/2000 Solect Technology Group Series C 33.5M
1/2004 Eyetel Imaging Series B 10.7M
2/2005 FibroGen Venture Round 0
3/2013 PTC Therapeutics Private Equity Round 60M
1/2016 Anaplan Series E 0
5/2014 Anaplan Series D 100M
11/2007 Virtual Iron Software Series D 13M
6/2006 Tengion Series B 50M
5/2015 MuleSoft Series G 0
7/2011 Radius Health Series C 66M
7/2013 Dicerna Pharmaceuticals Series C 0
7/2015 Giosis Series A 0
5/2007 Portola Pharmaceuticals Series C 70M
12/2011 Radius Health Private Equity Round 21.4M
1/2007 Brightcove Series C 59.5M
3/2009 Thumbplay Series F 0
5/2015 DocuSign Series F 0
9/2015 SevOne Series C 0
4/2008 Concert Pharmaceuticals Series C 0
12/2007 REVA Medical Venture Round 42M
5/2015 REGENXBIO Series D 0
2/2014 NJOY Private Equity Round 70M
11/2006 Concert Pharmaceuticals Series B 48.5M
12/2013 Larimar Therapeutics Series E 45M
1/2015 REGENXBIO Series C 30M
1/2016 Anaplan Series E 0
11/2015 Socar Series B 0
9/2015 SevOne Series C 0
7/2015 Translate Bio Series B 0
7/2015 Giosis Series A 0
7/2015 Qoo10-Indonesia Series A 0
5/2015 REGENXBIO Series D 0
5/2015 MuleSoft Series G 0
5/2015 DocuSign Series F 0
4/2015 Voyager Therapeutics Series B 0

Startup Industries

Startup Locations

Portfolio Current Status

Portfolio Employee Count

Name Price
Name Size Announced Date

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research